Venus Remedies Limited (BOM:526953)
1,221.80
+58.15 (5.00%)
At close: May 27, 2026
Venus Remedies Revenue
In the fiscal year ending March 31, 2026, Venus Remedies had annual revenue of 7.82B INR with 20.73% growth. Venus Remedies had revenue of 2.64B in the quarter ending March 31, 2026, with 35.59% growth.
Revenue
7.82B
Revenue Growth
+20.73%
P/S Ratio
1.99
Revenue / Employee
6.03M
Employees
1,298
Market Cap
15.55B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 7.82B | 1.34B | 20.73% |
| Mar 31, 2025 | 6.48B | 464.37M | 7.72% |
| Mar 31, 2024 | 6.01B | 459.40M | 8.27% |
| Mar 31, 2023 | 5.56B | -446.71M | -7.44% |
| Mar 31, 2022 | 6.00B | 520.57M | 9.50% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Morepen Laboratories | 17.87B |
| TTK Healthcare | 8.30B |
| Wanbury | 6.58B |
| Lincoln Pharmaceuticals | 6.52B |
| Fredun Pharmaceuticals | 5.91B |
| Fermenta Biotech | 5.44B |
| Syncom Formulations (India) | 5.21B |
| Kwality Pharmaceuticals | 5.06B |
Venus Remedies News
- 1 day ago - Venus Remedies announces ₹10 per share final dividend with record date set for August 2026 - Business Upturn
- 1 day ago - Venus Remedies schedules AGM for August 2026 and announces dividend - Business Upturn
- 5 days ago - Venus Remedies shares rally 4% after Saudi Arabia approves oncology drug Plerixafor for global marketing authorization - Business Upturn
- 5 days ago - Venus Remedies receives Saudi FDA approval for Plerixafor - Business Upturn
- 6 days ago - Venus Remedies promotes KYC awareness through social media - Business Upturn
- 1 year ago - Venus Remedies renews GMP certification from Ukraine’s SMDC for Baddi facility - Business Upturn
- 1 year ago - Venus Remedies shares jump 11% after US FDA grants QIDP status to novel antibiotic VRP-034 - Business Upturn
- 1 year ago - Venus Remedies gets US FDA grants QIDP status to novel polymyxin B formulation VRP-034 - Business Upturn